Patient Dosing in Phase 2 Clinical Trial of Puricase for Severe Gout Completed
Savient Pharmaceuticals, Inc (NASDAQ: SVNT), an emerging specialty pharmaceutical company engaged in developing, manufacturing and marketing pharmaceutical products that address unmet medical needs today announced the completion of patient dosing in a Phase 2 clinical trial of Puricase(R), a poly(ethylene glycol) (”PEG”) conjugate of recombinant porcine uricase (urate oxidase), for the treatment of severe, refractory gout.
